Merck & Co Inc (MRK)

MRK (NYSE:Drugs) EQUITY
$57.61
pos +0.56
+0.98%
Today's Range: 56.91 - 57.68 | MRK Avg Daily Volume: 8,903,300
Last Update: 06/30/16 - 4:01 PM EDT
Volume: 9,077,778
YTD Performance: 8.01%
Open: $57.15
Previous Close: $57.05
52 Week Range: $45.69 - $60.07
Oustanding Shares: 2,768,025,348
Market Cap: 153,846,848,842
6-Month Chart
TheStreet Ratings Grade for MRK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 5 6
Moderate Buy 0 0 0 0
Hold 7 7 7 7
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.17 2.17 2.17 2.08
Latest Dividend: 0.46
Latest Dividend Yield: 3.31%
Dividend Ex-Date: 06/13/16
Price Earnings Ratio: 34.10
Price Earnings Comparisons:
MRK Sector Avg. S&P 500
34.10 34.00 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.00% -0.42% 22.82%
GROWTH 12 Mo 3 Yr CAGR
Revenue -6.50 -0.20 -0.06
Net Income -62.60 -0.30 -0.11
EPS -61.60 -0.20 -0.08
Earnings for MRK:
EBITDA 13.92B
Revenue 39.50B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.91 $0.98 $3.72 $3.70
Number of Analysts 7 5 10 10
High Estimate $0.94 $1.00 $3.77 $3.88
Low Estimate $0.88 $0.97 $3.65 $3.34
Prior Year $0.86 $0.96 $3.59 $3.72
Growth Rate (Year over Year) 5.48% 2.50% 3.57% -0.59%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Jun 16, 2016 | 11:10 AM EDT

The market will 'continue to be rough' for investors with lower oil and Brexit worries weighing on investors minds, says TheStreet's Jim Cramer.

By

Jim Cramer

 | Jun 16, 2016 | 10:59 AM EDT

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is fond of Merck's stock.

By

Bret Jensen

 | Jun 12, 2016 | 2:00 PM EDT

Both have good capital appreciation potential.

By

Bret Jensen

 | Jun 10, 2016 | 10:00 AM EDT

Both have good capital appreciation potential.

By

Tim Melvin

 | Jun 1, 2016 | 5:00 PM EDT

Financial engineering such as stock buybacks aren't the best buy for companies.

updateMRK Investor Mtg.

May 24, 2016 | 7:27 AM EDT

MRK - Merck & Co Inc Annual Shareholders Meeting - 9AM

By

David Katz

 | May 18, 2016 | 7:00 AM EDT

We offer 10 names each in the Opportunistic Value portfolio and the Income-Oriented portfolio.

By

Bret Jensen

 | May 17, 2016 | 10:00 AM EDT

It is hard to see much growth in the market overall, until earnings growth returns.

By

David Katz

 | May 11, 2016 | 7:00 AM EDT

The expected legal deluge will be manageable thanks to JNJ's massive size and financial strength.

By

Jim Cramer

 | May 10, 2016 | 6:40 AM EDT

And Joe Papa can't stop the world. 

WMT held in very well during the 'Brexit' selling wave (...

The VIX has been hammered here, and we want to pick up some volatility BOUGHT VXX JULY 13 ...
The S&P continues to clear key upside hurdles after holding the symmetry support at th...
Market adding to gains and threatening to make it three days in a row of gains after sharp...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.